Showing results (31-40 of 91) with videos related to
Sort By:
Pageof 10
BMC Cancer|August 12, 2020
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatmentJean-David Fumet, Emeric Limagne, Marion Thibaudin, et al.Oncotarget|June 8, 2018
Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinomaAnne Aarnink, Corentin Richard, Caroline Truntzer, et al.Journal for Immunotherapy of Cancer|June 4, 2021
Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancerQuentin Klopfenstein, Valentin Derangère, Laurent Arnould, et al.Plos One|March 26, 2013
Isolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig modelPierre-Benoit Pagès, Olivier Facy, Pierre Mordant, et al.Current Opinion in Immunology|June 25, 2008
Immunogenic cancer cell death: a key-lock paradigmAntoine Tesniere, Lionel Apetoh, Francois Ghiringhelli, et al.Annals of Surgery|May 29, 2012
High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental studyOlivier Facy, Sophie Al Samman, Guy Magnin, et al.Scientific Reports|December 14, 2021
Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES imagesAnne Laure Le Page, Elise Ballot, Caroline Truntzer, et al.Journal of Cancer Research and Clinical Oncology|July 6, 2019
Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II studyFrancois Ghiringhelli, Julie Vincent, Leila Bengrine, et al.Anticancer Research|July 27, 2022
Metronomic Cyclophosphamide With Cisplatin and Bevacizumab for Refractory Anaplastic Ependymoma: A Retrospective StudyXavier Choderlos DE Laclos, Didier Frappaz, Guido Ahle, et al.ESMO Open|June 27, 2018
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancerJean-David Fumet, Nicolas Isambert, Alice Hervieu, et al.Pageof 10